[go: up one dir, main page]

WO2002030353A3 - INHIBITEURS DU NF-λB - Google Patents

INHIBITEURS DU NF-λB Download PDF

Info

Publication number
WO2002030353A3
WO2002030353A3 PCT/US2001/031866 US0131866W WO0230353A3 WO 2002030353 A3 WO2002030353 A3 WO 2002030353A3 US 0131866 W US0131866 W US 0131866W WO 0230353 A3 WO0230353 A3 WO 0230353A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
iλb
ikk
phosphorylation
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031866
Other languages
English (en)
Other versions
WO2002030353A2 (fr
Inventor
James F Callahan
Amy K Roshak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to US10/398,847 priority Critical patent/US20040024047A1/en
Priority to AU2002211663A priority patent/AU2002211663A1/en
Priority to JP2002533800A priority patent/JP2004523476A/ja
Priority to EP01979731A priority patent/EP1324759A4/fr
Publication of WO2002030353A2 publication Critical patent/WO2002030353A2/fr
Publication of WO2002030353A3 publication Critical patent/WO2002030353A3/fr
Anticipated expiration legal-status Critical
Priority to US11/237,232 priority patent/US20060030596A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne de nouveaux composés et de nouveaux procédés permettant de traiter des maladies au moyen d'inhibiteurs aminothiophène de la phosphorylation IKK-ß de IλB.
PCT/US2001/031866 2000-10-12 2001-10-12 INHIBITEURS DU NF-λB Ceased WO2002030353A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/398,847 US20040024047A1 (en) 2001-10-12 2001-10-12 Nf-kb inhibitors
AU2002211663A AU2002211663A1 (en) 2000-10-12 2001-10-12 Nf-$g(k)b inhibitors
JP2002533800A JP2004523476A (ja) 2000-10-12 2001-10-12 ＮＦ−κＢ阻害剤
EP01979731A EP1324759A4 (fr) 2000-10-12 2001-10-12 Inhibiteurs du nf-g(k)b
US11/237,232 US20060030596A1 (en) 2000-10-12 2005-09-28 NF-kappaB inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23975900P 2000-10-12 2000-10-12
US60/239,759 2000-10-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/237,232 Continuation US20060030596A1 (en) 2000-10-12 2005-09-28 NF-kappaB inhibitors

Publications (2)

Publication Number Publication Date
WO2002030353A2 WO2002030353A2 (fr) 2002-04-18
WO2002030353A3 true WO2002030353A3 (fr) 2002-06-27

Family

ID=22903601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031866 Ceased WO2002030353A2 (fr) 2000-10-12 2001-10-12 INHIBITEURS DU NF-λB

Country Status (4)

Country Link
EP (1) EP1324759A4 (fr)
JP (1) JP2004523476A (fr)
AU (1) AU2002211663A1 (fr)
WO (1) WO2002030353A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CA2427284A1 (fr) 2000-10-26 2002-05-30 Tularik Inc. Agents anti-inflammatoires
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
ATE414697T1 (de) * 2001-10-04 2008-12-15 Smithkline Beecham Corp Nf-kb-inhibitoren
JP2005509645A (ja) * 2001-10-30 2005-04-14 ファルマシア・コーポレーション 炎症処置用のヘテロ芳香族カルボキサミド誘導体
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
EP1532133A4 (fr) * 2002-06-06 2006-11-15 Smithkline Beecham Corp Inhibiteurs de nf-:b
JP2005532359A (ja) 2002-06-06 2005-10-27 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
EP1569924A4 (fr) * 2002-12-06 2007-02-21 Smithkline Beecham Corp Inhibiteurs du facteur nf-kb
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
MXPA06001775A (es) 2003-08-15 2006-05-17 Astrazeneca Ab Tiofenos substituidos y usos de los mismos.
MXPA06007054A (es) * 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
RU2397168C2 (ru) * 2004-01-05 2010-08-20 Астразенека Аб Производные тиофена в качестве ингибиторов снк 1
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
UA99699C2 (ru) 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Производные индолкарбоксамида и фармацевтическая композиция, которая их содержит
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
AU2009268875A1 (en) * 2008-07-09 2010-01-14 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2012046793A1 (fr) * 2010-10-07 2012-04-12 参天製薬株式会社 Nouvel inhibiteur de jak3 contenant, à titre de principe actif, un dérivé de thiophène portant un groupe uréido et un groupe aminocarbonyle à titre de substituants
EP2520292A1 (fr) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963750A (en) * 1973-08-09 1976-06-15 Beecham Group Limited Thiophene derivatives
JPH06143839A (ja) * 1992-11-06 1994-05-24 Dainippon Printing Co Ltd 熱転写シート
JPH06143838A (ja) * 1992-11-06 1994-05-24 Sankyo Kagaku Kk 感熱転写記録用色素

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963750A (en) * 1973-08-09 1976-06-15 Beecham Group Limited Thiophene derivatives
JPH06143839A (ja) * 1992-11-06 1994-05-24 Dainippon Printing Co Ltd 熱転写シート
JPH06143838A (ja) * 1992-11-06 1994-05-24 Sankyo Kagaku Kk 感熱転写記録用色素

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] (COLUMBUS, OHIO, USA); KAFUKU ET AL., XP002908443, accession no. STN Database accession no. 1995:259796 *
DATABASE HCAPLUS [online] (COLUMBUS, OHIO, USA); KAFUKU ET AL., XP002908444, accession no. STN Database accession no. 1995:330565 *
See also references of EP1324759A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
WO2002030353A2 (fr) 2002-04-18
EP1324759A2 (fr) 2003-07-09
AU2002211663A1 (en) 2002-04-22
EP1324759A4 (fr) 2004-05-12
JP2004523476A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2002030353A3 (fr) INHIBITEURS DU NF-λB
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002348135A1 (en) Methods for the treatment of addiction
AU2001285747A1 (en) Method for the treatment of tobacco
HUP0302739A3 (en) Method for the treatment of tobacco
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
WO2004087073A3 (fr) Traitement d'etats de demyelinisation
WO2005007123A3 (fr) Composes modulateurs de pin-1 et methodes d'utilisation associees
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
WO2004021988A3 (fr) Traitement de la douleur par inhibition de la map kinase p38
WO2002076396A3 (fr) Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferatives
EP1450820A4 (fr) Methode de traitement et de prevention de maladies inflammatoires
AU2002326991A1 (en) Methods for treating multiple sclerosis
WO2004060878A3 (fr) Inhibiteurs de phosphatases
WO2001044235A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10398847

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001979731

Country of ref document: EP

Ref document number: 2002533800

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001979731

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001979731

Country of ref document: EP